



Pharmacodynamic Evaluation of Fosfomycin against *Escherichia coli* and *Klebsiella* spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities

Nayara Helisandra Fedrigo,^a Josmar Mazucheli,^b James Albiero,^a
Danielle Rosani Shinohara,^a Fernanda Gomes Lodi,^a
Ana Cristina dos Santos Machado,^a  Sherwin K. B. Sy,^b
Maria Cristina Bronharo Tognim^a

Departamento de Ciências Básicas da Saúde, Universidade Estadual de Maringá, Maringá, PR, Brazil^a;
Programa de Pós-Graduação em Bioestatística, Departamento de Estatística, Universidade Estadual de Maringá, Maringá, PR, Brazil^b

ABSTRACT Fosfomycin is widely used for the treatment of uncomplicated urinary tract infection (UTI), and it has recently been recommended that fosfomycin be used to treat infections caused by multidrug-resistant (MDR) Gram-negative bacilli. Whether urine acidification can improve bacterial susceptibility to fosfomycin oral dosing regimens has not been analyzed. The MIC of fosfomycin for 245 Gram-negative bacterial isolates, consisting of 158 *Escherichia coli* isolates and 87 *Klebsiella* isolates which were collected from patients with urinary tract infections, were determined at pH 6.0 and 7.0 using the agar dilution method. Monte Carlo simulation of the urinary fosfomycin area under the concentration-time curve (AUC) after a single oral dose of 3,000 mg fosfomycin and the MIC distribution were used to determine the probability of target attainment (PTA). Fosfomycin was effective against *E. coli* (MIC₉₀ ≤ 16 µg/ml) but not against *Klebsiella* spp. (MIC₉₀ > 512 µg/ml). Acidification of the environment increased the susceptibility of 71% of the bacterial isolates and resulted in a statistically significant decrease in bacterial survival. The use of a regimen consisting of a single oral dose of fosfomycin against an *E. coli* isolate with an MIC of ≤64 mg/liter was able to achieve a PTA of ≥90% for a target pharmacodynamic index (AUC/MIC) of 23 in urine; PTA was not achieved when the MIC was higher than 64 mg/liter. The cumulative fractions of the bacterial responses (CFR) were 99% and 55% against *E. coli* and *Klebsiella* spp., respectively, based on simulated drug exposure in urine with an acidic pH of 6.0. A decrease of the pH from 7.0 to 6.0 improved the PTA and CFR of the target pharmacodynamic index in both *E. coli* and *Klebsiella* isolates.

KEYWORDS *Enterobacteriaceae*, fosfomycin, Monte Carlo simulation, acidic pH, pharmacodynamics, urinary tract infection

Urinary tract infections (UTIs) are the most common infections worldwide, and members of the family *Enterobacteriaceae* are the main pathogens responsible for UTIs (1). The rise in the rate of antibiotic resistance over the last several years has resulted in limited treatment options currently available for the treatment of infections caused by multidrug-resistant (MDR) bacteria. Fosfomycin is an old antibiotic agent frequently used to treat uncomplicated UTIs and has been reevaluated as a potential option for the treatment of infections caused by MDR Gram-negative bacteria (2). The dosage currently approved for the treatment of an uncomplicated UTI is a single

Received 23 November 2016 Returned for
modification 1 January 2017 Accepted 28
May 2017

Accepted manuscript posted online 12
June 2017

Citation Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy SKB, Tognim MCB. 2017. Pharmacodynamic evaluation of fosfomycin against *Escherichia coli* and *Klebsiella* spp. from urinary tract infections and the influence of pH on fosfomycin activities. *Antimicrob Agents Chemother* 61:e02498-16. <https://doi.org/10.1128/AAC.02498-16>.

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Maria Cristina Bronharo Tognim, mcbtognim@uem.br.

3,000-mg dose. However, for more complicated UTI cases (for which fosfomycin is not approved), multiple doses have been used. In parts of the world, including Brazil, where intravenous fosfomycin is not available, interest in regimens with multiple doses of oral fosfomycin for treating complicated UTIs and related infections has been renewed (3, 4).

Fosfomycin is a phosphonic acid derivative (*cis*-1,2-epoxypropyl phosphonic acid) isolated from a *Streptomyces* species (5). The molecule acts by inhibiting the first step in the biosynthesis of the bacterial cell wall and shows broad-spectrum bactericidal activity against both Gram-positive and Gram-negative pathogens (6). The parenteral formulation, fosfomycin disodium, is commercially available only in some European countries and Japan (7), whereas the oral formulation, fosfomycin tromethamine, is approved for use in Brazil and in other countries for the treatment of uncomplicated UTIs (8). Ninety-five percent of the absorbed drug is excreted by the kidney, which results in high drug concentrations in urine. These pharmacokinetic properties are favorable for the treatment of UTIs (9, 10).

The therapeutic response to antibacterial agents can be affected by the pH of body fluids (11). Previous studies have shown that fosfomycin exhibits optimal antimicrobial activity in acidic urine at pHs ranging from 5.0 to 6.0, whereas an acidic pH has an opposite effect on the MICs of fluoroquinolones, including ciprofloxacin (12–17). However, there is a lack of information related to whether an acidic environment can enhance bacterial susceptibility to the current commercial fosfomycin oral dosing regimen for the treatment of uncomplicated UTIs. This study utilized simulations of fosfomycin pharmacokinetics (PK) and a target pharmacodynamic (PD) index of fosfomycin to investigate whether the pH environment has a significant effect on the susceptibility of *Escherichia coli* and *Klebsiella* isolates collected from patients with uncomplicated UTIs to the fosfomycin oral dosing regimen and to determine the extent of bacterial killing due to fosfomycin that was achieved in urine acidified to pH 6.0. The current analyses are aimed at the evaluation of fosfomycin only for the treatment of uncomplicated UTIs.

RESULTS

In vitro susceptibility and effect of pH. Table 1 presents the antimicrobial susceptibility profiles of 245 *E. coli* and *Klebsiella* urinary isolates at pH 6.0 and 7.0. *E. coli* isolates from patients with urinary tract infection were highly susceptible to fosfomycin at pH 7.0 with an MIC₉₀ of ≤ 16 $\mu\text{g/ml}$. In contrast, fosfomycin was not active against *Klebsiella* spp. A high fosfomycin MIC₉₀ of ≥ 512 $\mu\text{g/ml}$ was observed against these isolates.

The *in vitro* activity of fosfomycin against the two bacterial species tested was improved by acidification of the growth medium (Table 1). The fosfomycin MIC against *E. coli* and *Klebsiella* spp. was reduced for 71% (175/245) of the isolates. The MIC₉₀ against *E. coli* and *Klebsiella* spp. was 2-fold lower in the lower-pH environment. Several strains that were previously resistant to fosfomycin at pH 7.0 became susceptible at pH 6.0, with the greatest effects being observed for the *Klebsiella* spp., given the Clinical and Laboratory Standards Institute (CLSI) breakpoint value of ≥ 64 $\mu\text{g/ml}$.

To evaluate whether the decrease in MIC values was statistically significant, we utilized a survival analysis approach, replacing the time component with MIC values. Figure 1 shows the survival curves at pH 6.0 and 7.0 for *E. coli* and *Klebsiella* spp. isolated from patients with UTIs. Applying the log-rank test to compare the two curves, we rejected the hypothesis that the survival curves were equal ($P = 0.0001$ for both, log-rank test).

Pharmacodynamic analyses. Figure 2 shows the probability of target attainment (PTA) for an area under the concentration-time curve (AUC)/MIC of 23 for a fosfomycin dosing regimen of a single dose of 3,000 mg and the MIC frequency of fosfomycin by microorganism type at pH 6.0 and 7.0. Oral fosfomycin achieved a PTA of $\geq 90\%$ for the target of an AUC/MIC of 23 at an MIC of ≤ 4 $\mu\text{g/ml}$ in serum and an MIC of ≤ 64 $\mu\text{g/ml}$ in urine, indicating that the antimicrobial coverage was sufficient to achieve the MIC₉₀.

TABLE 1 *In vitro* susceptibilities to fosfomycin of *E. coli* and *Klebsiella* spp. clinical isolates from patients with UTIs at pH 6.0 and 7.0^a

Microorganism	No. of strains	pH of test	No. of isolates with the following MIC (μg/ml):												MIC (mg/liter)			% of isolates				
															50%	90%	CLSI		EUCAST			
			0.25	0.5	1	2	4	8	16	32	64	128	256	512			>512	S	I	R	S	R
<i>Escherichia coli</i>	158	7.0	—	—	3	61	54	19	6	10	3	1	—	—	1	4	16	98	1	1	97	3
		6.0	—	9	63	52	12	13	5	2	1	—	—	—	1	2	8	99		1	98	2
<i>Klebsiella</i> spp. ^b	87	7.0	—	—	—	—	—	—	2	2	—	23	21	22	17	256	>512	5	26	69	5	95
		6.0	—	—	—	—	—	2	3	6	15	26	19	7	9	128	512	30	30	40	13	87

^a—, no isolate; S, susceptible; I, intermediate susceptibility; R, resistant; CLSI, Clinical and Laboratory Standards Institute interpretative criteria (susceptible, MIC of ≤64 μg/ml; intermediate, MIC of 128 μg/ml; resistant, MIC of ≥256 μg/ml; EUCAST, European Committee on Antimicrobial Susceptibility Testing interpretative criteria (susceptible, MIC of ≤32 μg/ml; resistant, MIC of ≥32 μg/ml).

^bThe species isolated included *Klebsiella pneumoniae* (n = 81) and *K. oxytoca* (n = 6).




FIG 1 Survival-type antimicrobial susceptibility curves for *Escherichia coli* isolates ($n = 158$) and *Klebsiella* isolates ($n = 87$) from patients with urinary tract infections stratified on the basis of pHs of 6.0 (solid line) and 7.0 (dotted line).

against *E. coli* isolates at both pH 6.0 and 7.0. The oral dosing regimen was not able to achieve a PTA of $\geq 90\%$ at the MIC_{50}/MIC_{90} against *Klebsiella* isolates at pH 6.0 or 7.0. The breakpoints for susceptibility of both European Committee on Antimicrobial Susceptibility Testing (EUCAST) ($MIC \leq 32 \mu\text{g/ml}$) and CLSI ($MIC = 64 \mu\text{g/ml}$) were achieved in urine using the criterion of a PTA of $\geq 90\%$ for a target of an AUC/MIC ratio of 23. An acidic pH resulted in a higher PTA at the MIC_{50} and MIC_{90} . However, this condition was not sufficient for the fosfomycin regimen against bacteria harboring fosfomycin resistance with an MIC of $>64 \mu\text{g/ml}$ on the basis of the AUC/MIC PD index.

A summary of the cumulative fractions of the bacterial responses (CFR) by fosfomycin dosing regimen at pH 6.0 and 7.0 in serum and urine is shown in Table 2. For the *Klebsiella spp.*, the CFR improved from 28% to 55% when the urine pH was changed from 7.0 to 6.0. There was excellent coverage against *E. coli* regardless of the urine pH.

DISCUSSION

MDR Gram-negative bacterial infections have prompted the revival of fosfomycin (2, 18). Our study showed that an oral fosfomycin dosing regimen that is commonly used in clinical practice for the treatment of uncomplicated UTIs was more likely to achieve the PTA at the MIC_{90} against *E. coli*. Fosfomycin was less active against *Klebsiella spp.*, as shown by a decrease of the PTA of the fosfomycin PD target index of an AUC/MIC of 23 in both serum and urine to below 90%.

The current study evaluated the MICs only of *Enterobacteriaceae*. Our findings for the fosfomycin MIC against *E. coli* and *Klebsiella spp.* were consistent with those reported in recent studies that evaluated *in vitro* susceptibility profiles (1, 19, 20). Fosfomycin presented high levels of activity against *E. coli*. However, this drug was less active against *Klebsiella spp.*, which displayed a higher MIC distribution (21–23). Falagas et al. reported that the fosfomycin MIC distribution can be quite variable and can also be influenced by several factors, including bacterial species (24). A retrospective study from a hospital in Oxfordshire, UK, found the rate of fosfomycin resistance to be 1% for *E. coli* isolates but 19% for *Klebsiella* isolates when oral fosfomycin was used to




FIG 2 Fosfomycin MIC frequency in 158 *Escherichia coli* and 87 *Klebsiella* clinical isolates at pH 6.0 and 7.0 and probability of target attainment of an AUC/MIC of 23 against *E. coli* (right) and *Klebsiella* spp. (left) in serum (top) and urine (bottom) matrices for a fosfomycin dosing regimen consisting of a single dose of 3,000 mg in 10,000 virtual patients. PTA, probability of target attainment; AUC, area under the concentration-time curve.

treat UTIs (25). Their results corroborated the CFR estimated for the Maringá State University Hospital in Brazil. The current study shows that the standard single oral dose of fosfomycin is inadequate when *Klebsiella* spp. are the predominant bacteria, even in uncomplicated UTIs.

The success of antimicrobial therapy against UTIs in a population can be estimated by the PK/PD profiles inferred from the drug concentrations at the site of action (26). The fosfomycin dosing regimen tested showed sufficient antimicrobial coverage for bacteria with MICs of up to 64 $\mu\text{g/ml}$ in urine. A study by Rhodes et al. found that a single oral dose of 3,000 mg of fosfomycin was suitable against pathogens with an MIC value of up to 4 $\mu\text{g/ml}$ in the prostate (27). On the basis of simulations, an oral dose of 3,000 mg fosfomycin was effective against *E. coli* isolates at both pH 6.0 and 7.0; however, the fosfomycin dosing regimen evaluated would not achieve a satisfactory PTA at an MIC of >64 $\mu\text{g/ml}$. Consequently, a PTA of $\geq 90\%$ for the MIC₅₀ against *Klebsiella* isolates was unattainable.

Albiero and colleagues evaluated treatment regimens consisting of fosfomycin

TABLE 2 CFR at AUC/MIC of 23 for a single 3,000-mg oral dose of fosfomycin against a collection of clinical isolates by bacterial type

Bacterial type	% of isolates			
	pH 6		pH 7	
	Serum	Urine	Serum	Urine
<i>E. coli</i>	93.5	99	85	99
<i>Klebsiella</i> spp.	2.7	55	0.6	28




FIG 3 Molecular structure of fosfomycin and pK_a values derived from the Chemicalize database (<https://chemicalize.com/#/calculation>).

alone and in combination with meropenem and also showed that the administration of fosfomycin as monotherapy against KPC-2-producing *K. pneumoniae* (MIC_{50} 64 $\mu\text{g/ml}$) was not able to achieve a PTA of $\geq 90\%$ even at higher dosages and when given as 3-h infusions in patients with normal renal function or renal impairment (28). Combination of fosfomycin with a carbapenem is required to confer bacterial susceptibility to both fosfomycin and meropenem in KPC-producing *K. pneumoniae* (28).

CLSI recommends a breakpoint of $\leq 64 \mu\text{g/ml}$ to differentiate *E. coli* and *Enterococcus faecalis* isolates from patients with UTIs susceptible and resistant to oral fosfomycin (29). The EUCAST MIC breakpoint of 32 $\mu\text{g/ml}$ for the susceptibility of *Enterobacteriaceae* and *Staphylococcus* spp. to intravenous fosfomycin, irrespective of the site of infection, is lower (30). Fosfomycin is excreted in the active form in the urine via the kidneys and might achieve *in vivo* concentrations above the usual MIC against common uropathogens (9, 10). The same studies demonstrated that serum susceptibility data overestimated the resistance of urinary isolates in the presence of high urine antibiotic levels (10, 31–33). Even though only the higher doses may be required to achieve the PTA for an MIC of 64 $\mu\text{g/ml}$, fosfomycin becomes highly concentrated in the urine. It remains to be evaluated in a clinical setting whether the current oral dosing regimen supplemented with urine acidification would be sufficient to treat UTIs caused by MDR bacteria or whether a dose adjustment is required.

Acidification of the bacterial growth medium was an important factor affecting the efficacy of fosfomycin and, consequently, improved the antimicrobial coverage against the majority of the *E. coli* and *Klebsiella* isolates studied (71%). There was a significant difference in the MIC for these isolates between pH 6.0 and 7.0, which corroborates the findings of other studies that demonstrated a pH effect on the *in vitro* activity of antimicrobial agents and the therapeutic response (12–17, 34, 35). The enhanced activity of fosfomycin in an acidic environment can be explained by its physicochemical properties. The molecular structure of fosfomycin contains an epoxide ring linked to a phosphate group that is ionized, depending on the pH. It has two pK_a values: pK_a 1 is 1.25, and pK_a 2 is 7.82 (Fig. 3). The fosfomycin molecule is less protonated at pH 6.0, where the predominant microspecies has an electric charge of -1 , than at pH 7.0, where the predominant microspecies has an electric charge of -2 (Fig. 4). At an acidic pH where fosfomycin is in its least ionized and more lipophilic state, a major fraction of the available antibiotic molecules can enter the bacteria, resulting in greater antimicrobial activity in acidic urine.

It is known that some urinary pathogens, such as *Proteus mirabilis* and *Klebsiella* species, are capable of producing ammonia from urea, resulting in an increased urine pH (36). The urine alkalization caused by these microorganisms can hinder antimicrobial treatment using fosfomycin. Alternative complementary strategies have been used for the treatment of UTIs, including the use of agents that acidify the urine (37). Ascorbic acid (vitamin C) is regarded as safe and effective in altering the urinary pH (14, 38). It is often used as an agent to prevent UTI, although there is no evidence to support this indication (39). Some studies have shown the benefits of using vitamin C together with antimicrobials. Carlsson et al. investigated the inhibition of growth of different bacterial strains, including *E. coli*, by ascorbic acid at various pH levels in




FIG 4 Relationship between the microspecies distribution percentage for fosfomycin and pH adapted from the Chemicalize database (<https://chemicalize.com/#/calculation>).

human urine and demonstrated that vitamin C may be used for the treatment and prophylaxis of UTIs (38). However, its use should not be excessive because excess ascorbic acid can induce tissue damage and salt precipitation, causing urinary stones and/or encrustation in humans (14).

The present study has some limitations. First, the isolates came from a public hospital that provides services for the population of 808,241 people residing in the Maringá metropolitan region, which covers 30 municipalities, but this population may not be representative of the overall Brazilian population. Second, the narrow range of pH values investigated with the *E. coli* and *Klebsiella* isolates (6.0 to 7.0) precludes the ability to determine the effect of the whole spectrum of the pH range on the behavior of fosfomycin according to pH. We verified in the survival analysis that the decrease in MIC values with a decrease in pH was statistically significant.

In conclusion, PK/PD analyses of fosfomycin showed that a lower physiological pH improved attainment of the target PD index in the majority of the *E. coli* isolates but not in *Klebsiella* species. Fosfomycin activity was improved at an acidic pH; urine acidification can easily be achieved with supplemental vitamin C during fosfomycin treatment of uncomplicated UTI in clinical practice.

MATERIALS AND METHODS

Bacterial isolates. A total of 245 nonduplicated consecutive *E. coli* and *Klebsiella* isolates recovered from patients with suspected UTIs with a colony count of greater than 10^5 CFU per milliliter were selected from the medical microbiology laboratory organism bank of the Maringá State University Hospital. All isolates were identified by means of the BD Phoenix automated microbiology system and were stored at -20°C in Trypticase soy broth (Difco Laboratories, Detroit, MI) with 30% glycerol until they were tested. The isolates were recovered on MacConkey agar plates to verify the purity of the culture. These plates were incubated at $35 \pm 2^{\circ}\text{C}$ in ambient air for 24 h. The isolates, which were collected between January 2011 and June 2015, included 158 *Escherichia coli* isolates and 87 *Klebsiella* isolates. Only one

isolate per patient was included in the study. The study was approved by the “Permanent Committee of Ethics in Research Involving Human Beings” of the Maringá State University (CAAE no. 318.0.093.000-11).

Antimicrobial agents. Fosfomycin (Sigma-Aldrich, St. Louis, MO, USA) was purchased from LabCompanny (Londrina, Paraná, Brazil). Fosfomycin was dissolved in water to form a 10- μ g/ml stock solution, which was stored at -20°C (stock solution).

Antimicrobial susceptibility testing. The susceptibilities of the isolates to fosfomycin were determined by the agar dilution method, as described in CLSI guidelines (29, 40), at pH 6.0 and 7.0 using Mueller-Hinton agar (MHA; Difco Laboratories, Detroit, MI), which was supplemented with an additional 25 μ g/ml of glucose-6-phosphate (G6-phosphate). The pH of the MHA was adjusted by adding either 1 N HCl or NaOH and tested using a pH meter before autoclaving. During the experiment, G6-phosphate was diluted along with 2-fold serial dilutions of antimicrobial agent in water in glass tubes. After shaking, the serial dilution containing the antimicrobial agent plus G6-phosphate was incorporated into liquid MHA, which was kept in a constant 50°C water bath. The pH of the medium to which the antimicrobial solution plus G6-phosphate was added was then verified using Merck universal indicator strips. The solution was then poured onto plates.

The test isolates and ATCC reference strains were suspended in sterile Mueller-Hinton broth (Difco Laboratories, Detroit, MI) and adjusted to the equivalent of a 0.5 McFarland standard. Cell suspensions were further diluted and were delivered onto plates using a Steers replicator, which carried approximately 10^4 CFU of each isolate. The inoculated plates were incubated in ambient air at $35 \pm 2^{\circ}\text{C}$ for 16 to 20 h.

The tested fosfomycin concentrations ranged from 0.25 to 512 μ g/ml. The MIC against a bacterial strain was defined as the lowest concentration that inhibited visible growth of the organism. MIC values were determined 2 to 4 times per isolate to identify the modal value, which is reported in this study. Control strains, including *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, and *Enterococcus faecalis* ATCC 29212, were included in each set of tests.

Interpretation of susceptibility results. The susceptibility categories by MIC were determined using both the CLSI interpretive criteria for urinary tract isolates of *E. coli* and *E. faecalis* (29) and the EUCAST interpretive criteria for all isolates of the *Enterobacteriaceae* (30).

Pharmacokinetics and Monte Carlo simulation. Monte Carlo simulation of 10,000 virtual exposure parameters was carried out in R software (v.3.1.1; R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria). Exposure data previously reported in the literature and the package insert for a single oral dose of 3,000 mg fosfomycin in both serum and urine were used to generate simulated distributions for the AUC for serum ($\text{AUC}_{\text{serum}}$) of $296 \pm 46.4 \mu\text{g} \cdot \text{h/ml}$ for healthy volunteers (41) and an average urine concentration ($C_{\text{avg,urine}}$) of $537 \pm 252 \mu\text{g/ml}$ within 6 to 8 h after a single dose in the fed state (42). The fosfomycin AUC for urine ($\text{AUC}_{\text{urine}}$) was computed as $C_{\text{avg,urine}}$ multiplied by 8 h ($\text{AUC}_{\text{urine}}$ 4,296 $\pm 2,016 \mu\text{g} \cdot \text{h/ml}$). A log-normal distribution was assumed in order to avoid negative exposure values. In the simulation, the variability, characterized by the coefficient of variation or the $\text{AUC}_{\text{serum}}$, was increased to 50% to mimic the variability in patients. The level of protein binding of fosfomycin in plasma is negligible (42). The area under the concentration-time curve-to-MIC (AUC/MIC) ratios in serum and urine for the single oral dose regimen were then determined and compared to the target PD index determined from the literature (43).

Pharmacodynamics. PD analyses were performed using Monte Carlo simulations based on the distribution of the AUC in urine and serum. This method accounts for the variability in the pharmacokinetics of the drug and the distribution of MIC data to determine the probability of reaching a target AUC/MIC ratio of 23 in serum and urine. This target value was selected on the basis of the report by Lepak et al. showing that the 24-h AUC/MIC ratio of 23 after fosfomycin injection in the neutropenic murine thigh infection model is associated with stasis in *Enterobacteriaceae* (43).

The PTA was determined from the distribution of the AUC/MIC in incremental MIC values. The PTA for a drug regimen was considered adequate when $\geq 90\%$ of the simulated population achieved or exceeded the target PD index (44, 45). CFR for a single oral 3-g fosfomycin dose at an AUC/MIC of 23 was computed as the summation of the density or percentage of bacteria at each MIC across the distribution multiplied by the PTA value at the MIC for the regimen (46, 47).

Statistical analysis. Survival analysis for interval-censored data was used to compare the effect of pH on the survival curve for all bacteria used in the study. For the comparison of the survival curves, the log-rank test was used to determine whether the curves were significantly different (48). A *P* value of <0.05 was considered significant.

ACKNOWLEDGMENTS

The funding agency, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), had no role in the study design, data collection and interpretation, or the decision to submit the work for publication, as these government funds are designed to encourage training in higher education in Brazil and cover only the cost of laboratory materials.

REFERENCES

- Demir T, Buyukguclu T. 2013. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. *Int J Infect Dis* 17:e966–e970. <https://doi.org/10.1016/j.ijid.2013.04.005>.
- Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with

- fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. *Antimicrob Agents Chemother* 56:5744–5748. <https://doi.org/10.1128/AAC.00402-12>.
3. Giancola SE, Mahoney MV, Hogan MD, Raux BR, McCoy C, Hirsch EB. 2017. Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: patient characteristics and outcomes. *Chemotherapy* 62:100–104. <https://doi.org/10.1159/000449422>.
 4. Los-Arcos I, Pigrau C, Rodriguez-Pardo D, Fernandez-Hidalgo N, Andreu A, Larrosa N, Almirante B. 2015. Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis. *Antimicrob Agents Chemother* 60:1854–1858. <https://doi.org/10.1128/AAC.02611-15>.
 5. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S. 1969. Phosphonomycin, a new antibiotic produced by strains of streptomycetes. *Science* 166:122–123. <https://doi.org/10.1126/science.166.3901.122>.
 6. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. 1996. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. *Structure* 4:1465–1474. [https://doi.org/10.1016/S0969-2126\(96\)00153-0](https://doi.org/10.1016/S0969-2126(96)00153-0).
 7. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, Jacobs MR, Bonomo RA. 2010. In vitro activity of fosfomycin against bla_{KPC}-containing *Klebsiella pneumoniae* isolates, including those nonsusceptible to tigecycline and/or colistin. *Antimicrob Agents Chemother* 54:526–529. <https://doi.org/10.1128/AAC.01235-09>.
 8. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. 2008. Fosfomycin: use beyond urinary tract and gastrointestinal infections. *Clin Infect Dis* 46:1069–1077. <https://doi.org/10.1086/527442>.
 9. Frossard M, Joukhadar C, Erovic BM, Dittich P, Mrass PE, Van Houte M, Burgmann H, Georgopoulos A, Muller M. 2000. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. *Antimicrob Agents Chemother* 44:2728–2732. <https://doi.org/10.1128/AAC.44.10.2728-2732.2000>.
 10. Frimodt-Moller N. 2002. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. *Int J Antimicrob Agents* 19:546–553. [https://doi.org/10.1016/S0924-8579\(02\)00105-X](https://doi.org/10.1016/S0924-8579(02)00105-X).
 11. Milne BD, Scribner MH, Crawford MA. 1958. Non-ionic diffusion and the excretion of weak acids and bases. *Am J Med* 24:709–729. [https://doi.org/10.1016/0002-9343\(58\)90376-0](https://doi.org/10.1016/0002-9343(58)90376-0).
 12. Burian A, Erdogan Z, Jandrisits C, Zeitlinger M. 2012. Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine. *Pharmacology* 90:281–287. <https://doi.org/10.1159/000342423>.
 13. Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M. 2011. Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. *Res Microbiol* 162:249–252. <https://doi.org/10.1016/j.resmic.2011.01.004>.
 14. Yang L, Wang K, Li H, Denstedt JD, Cadieux PA. 2014. The influence of urinary pH on antibiotic efficacy against bacterial uropathogens. *Urology* 84:731.e1–7. <https://doi.org/10.1016/j.urolgy.2014.04.048>.
 15. Kamberi M, Tsutsumi K, Kotegawa T, Kawano K, Nakamura K, Niki Y, Nakano S. 1999. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. *Antimicrob Agents Chemother* 43:525–529.
 16. Lorian V, Sabath LD. 1970. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. *Appl Microbiol* 20:754–756.
 17. Dalhoff A, Schubert S, Ullmann U. 2005. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide. *Infection* 33(Suppl 2):S36–S43.
 18. Seroy JT, Grim SA, Reid GE, Wellington T, Clark NM. 2016. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. *J Antimicrob Chemother* 71:2563–2568. <https://doi.org/10.1093/jac/dkw178>.
 19. Villar HE, Jugo MB, Macan A, Visser M, Hidalgo M, Maccallini GC. 2014. Frequency and antibiotic susceptibility patterns of urinary pathogens in male outpatients in Argentina. *J Infect Dev Ctries* 8:699–704. <https://doi.org/10.3855/jidc.3766>.
 20. Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan HM. 2015. Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer? *Urol Ann* 7:26–30. <https://doi.org/10.4103/0974-7796.148585>.
 21. Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K. 2015. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. *Int Urol Nephrol* 47:1059–1066. <https://doi.org/10.1007/s11255-015-1018-9>.
 22. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. 2010. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, *Enterobacteriaceae* infections: a systematic review. *Lancet Infect Dis* 10:43–50. [https://doi.org/10.1016/S1473-3099\(09\)70325-1](https://doi.org/10.1016/S1473-3099(09)70325-1).
 23. Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. 2016. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. *Int J Antimicrob Agents* 47:269–285. <https://doi.org/10.1016/j.ijantimicag.2016.02.001>.
 24. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. 2016. Fosfomycin. *Clin Microbiol Rev* 29:321–347. <https://doi.org/10.1128/CMR.00068-15>.
 25. Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, Jones N. 2016. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. *BMC Infect Dis* 16:556. <https://doi.org/10.1186/s12879-016-1888-1>.
 26. Gonzalez D, Schmidt S, Derendorf H. 2013. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. *Clin Microbiol Rev* 26:274–288. <https://doi.org/10.1128/CMR.00092-12>.
 27. Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, Frauman AG, Maxwell KM, Zembower TR, Scheetz MH. 2015. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. *J Antimicrob Chemother* 70:2068–2073. <https://doi.org/10.1093/jac/dkv067>.
 28. Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC. 2016. Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 60:4128–4139. <https://doi.org/10.1128/AAC.03099-15>.
 29. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th informational supplement, 26th ed. M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
 30. European Committee on Antimicrobial Susceptibility Testing. 2016. Breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/clinical_breakpoints/.
 31. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. 1974. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. *N Engl J Med* 291:1159–1163. <https://doi.org/10.1056/NEJM197411282912204>.
 32. Pea F, Pavan F, Di Qual E, Brollo L, Nascimben E, Baldassarre M, Furlanut M. 2003. Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. *J Chemother* 15:563–567. <https://doi.org/10.1179/joc.2003.15.6.563>.
 33. Cunha BA. 2012. Predicting in vivo effectiveness from in vitro susceptibility: a step closer to performing testing of uropathogens in human urine. *Scand J Infect Dis* 44:714–715. <https://doi.org/10.3109/00365548.2012.673731>.
 34. Danby CS, Boikov D, Rautemaa-Richardson R, Sobel JD. 2012. Effect of pH on in vitro susceptibility of *Candida glabrata* and *Candida albicans* to 11 antifungal agents and implications for clinical use. *Antimicrob Agents Chemother* 56:1403–1406. <https://doi.org/10.1128/AAC.05025-11>.
 35. Cunha BA. 2016. An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH. *Eur J Clin Microbiol Infect Dis* 35:521–526. <https://doi.org/10.1007/s10096-016-2577-0>.
 36. Vince A, Dawson AM, Park N, O'Grady F. 1973. Ammonia production by intestinal bacteria. *Gut* 14:171–177. <https://doi.org/10.1136/gut.14.3.171>.
 37. Reid G. 1999. Potential preventive strategies and therapies in urinary tract infection. *World J Urol* 17:359–363. <https://doi.org/10.1007/s003450050161>.
 38. Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JO. 2001. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. *Nitric Oxide* 5:580–586. <https://doi.org/10.1006/niox.2001.0371>.
 39. Hickling DR, Nitti VW. 2013. Management of recurrent urinary tract infections in healthy adult women. *Rev Urol* 15:41–48.

40. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
41. Bergan T. 1990. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. *Infection* 18(Suppl 2):S65–S69. <https://doi.org/10.1007/BF01643430>.
42. Food and Drug Administration. 2011. Monurol (fosfomycin tromethamine) package insert. Food and Drug Administration, Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050717s007lbl.pdf.
43. Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR. 2017. In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 61:e00476-17. <https://doi.org/10.1128/AAC.00476-17>.
44. Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR. 2015. *N*-Acetyltransferase genotypes and the pharmacokinetics and tolerability of *para*-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. *Antimicrob Agents Chemother* 59:4129–4138. <https://doi.org/10.1128/AAC.04049-14>.
45. de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR. 2014. Pharmacokinetics of *para*-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. *Antimicrob Agents Chemother* 58: 6242–6250. <https://doi.org/10.1128/AAC.03073-14>.
46. Sy SK, Derendorf H. 2014. Pharmacometrics in bacterial infections, p 229–258. *In* Schmidt S, Derendorf H (ed), *Applied pharmacometrics*, 1st ed. Springer, New York, NY.
47. Sy SK, Zhuang L, Derendorf H. 2016. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. *Expert Opin Drug Metab Toxicol* 12:93–114. <https://doi.org/10.1517/17425255.2016.1123250>.
48. van de Kasstele J, van Santen-Verheuvél MG, Koedijk FD, van Dam AP, van der Sande MA, de Neeling AJ. 2012. New statistical technique for analyzing MIC-based susceptibility data. *Antimicrob Agents Chemother* 56:1557–1563. <https://doi.org/10.1128/AAC.05777-11>.